Literature DB >> 25860784

Peptide Triazole Inactivators of HIV-1 Utilize a Conserved Two-Cavity Binding Site at the Junction of the Inner and Outer Domains of Env gp120.

Rachna Aneja1, Adel A Rashad1, Huiyuan Li1, Ramalingam Venkat Kalyana Sundaram1,2, Caitlin Duffy1, Lauren D Bailey1, Irwin Chaiken1.   

Abstract

We used coordinated mutagenesis, synthetic design, and flexible docking to investigate the structural mechanism of Env gp120 encounter by peptide triazole (PT) inactivators of HIV-1. Prior results demonstrated that the PT class of inhibitors suppresses binding at both CD4 and coreceptor sites on Env and triggers gp120 shedding, leading to cell-independent irreversible virus inactivation. Despite these enticing anti-HIV-1 phenotypes, structural understanding of the PT-gp120 binding mechanism has been incomplete. Here we found that PT engages two inhibitor ring moieties at the junction between the inner and outer domains of the gp120 protein. The results demonstrate how combined occupancy of two gp120 cavities can coordinately suppress both receptor and coreceptor binding and conformationally entrap the protein in a destabilized state. The two-cavity model has common features with small molecule gp120 inhibitor binding sites and provides a guide for further design of peptidomimetic HIV-1 inactivators based on the PT pharmacophore.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25860784      PMCID: PMC4497506          DOI: 10.1021/acs.jmedchem.5b00073

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  44 in total

1.  Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.

Authors:  Alyssa C Biorn; Simon Cocklin; Navid Madani; Zhihai Si; Tijana Ivanovic; James Samanen; Donald I Van Ryk; Ralph Pantophlet; Dennis R Burton; Ernesto Freire; Joseph Sodroski; Irwin M Chaiken
Journal:  Biochemistry       Date:  2004-02-24       Impact factor: 3.162

2.  Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity.

Authors:  Barna Dey; Marie Pancera; Krisha Svehla; Yuuei Shu; Shi-Hua Xiang; Jeffrey Vainshtein; Yuxing Li; Joseph Sodroski; Peter D Kwong; John R Mascola; Richard Wyatt
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

3.  Opening Fronts in HIV Vaccine Development: Targeting reservoirs to clear and cure.

Authors:  Robert F Siliciano
Journal:  Nat Med       Date:  2014-05       Impact factor: 53.440

4.  Rapid measurement of binding constants and heats of binding using a new titration calorimeter.

Authors:  T Wiseman; S Williston; J F Brandts; L N Lin
Journal:  Anal Biochem       Date:  1989-05-15       Impact factor: 3.365

5.  HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.

Authors:  Susan M Schader; Susan P Colby-Germinario; Peter K Quashie; Maureen Oliveira; Ruxandra-Ilinca Ibanescu; Daniela Moisi; Thibault Mespléde; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

6.  Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors.

Authors:  Karyn McFadden; Patricia Fletcher; Fiorella Rossi; Muddagowda Umashankara; Vanessa Pirrone; Srivats Rajagopal; Hosahudya Gopi; Fred C Krebs; Julio Martin-Garcia; Robin J Shattock; Irwin Chaiken
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

7.  Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.

Authors:  Lei Chen; Young Do Kwon; Tongqing Zhou; Xueling Wu; Sijy O'Dell; Lisa Cavacini; Ann J Hessell; Marie Pancera; Min Tang; Ling Xu; Zhi-Yong Yang; Mei-Yun Zhang; James Arthos; Dennis R Burton; Dimiter S Dimitrov; Gary J Nabel; Marshall R Posner; Joseph Sodroski; Richard Wyatt; John R Mascola; Peter D Kwong
Journal:  Science       Date:  2009-11-20       Impact factor: 47.728

8.  Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1.

Authors:  Hosahudya Gopi; M Umashankara; Vanessa Pirrone; Judith LaLonde; Navid Madani; Ferit Tuzer; Sabine Baxter; Isaac Zentner; Simon Cocklin; Navneet Jawanda; Shendra R Miller; Arne Schön; Jeffrey C Klein; Ernesto Freire; Fred C Krebs; Amos B Smith; Joseph Sodroski; Irwin Chaiken
Journal:  J Med Chem       Date:  2008-04-11       Impact factor: 7.446

9.  Analysis of the interaction between human interleukin-5 and the soluble domain of its receptor using a surface plasmon resonance biosensor.

Authors:  T A Morton; D B Bennett; E R Appelbaum; D M Cusimano; K O Johanson; R E Matico; P R Young; M Doyle; I M Chaiken
Journal:  J Mol Recognit       Date:  1994-03       Impact factor: 2.137

10.  CD4-induced activation in a soluble HIV-1 Env trimer.

Authors:  Miklos Guttman; Natalie K Garcia; Albert Cupo; Tsutomu Matsui; Jean-Philippe Julien; Rogier W Sanders; Ian A Wilson; John P Moore; Kelly K Lee
Journal:  Structure       Date:  2014-06-12       Impact factor: 5.006

View more
  12 in total

1.  Chemical optimization of macrocyclic HIV-1 inactivators for improving potency and increasing the structural diversity at the triazole ring.

Authors:  Adel A Rashad; Kriti Acharya; Ann Haftl; Rachna Aneja; Alexej Dick; Andrew P Holmes; Irwin Chaiken
Journal:  Org Biomol Chem       Date:  2017-09-26       Impact factor: 3.876

2.  Disulfide Sensitivity in the Env Protein Underlies Lytic Inactivation of HIV-1 by Peptide Triazole Thiols.

Authors:  Lauren D Bailey; Ramalingam Venkat Kalyana Sundaram; Huiyuan Li; Caitlin Duffy; Rachna Aneja; Arangassery Rosemary Bastian; Andrew P Holmes; Kantharaju Kamanna; Adel A Rashad; Irwin Chaiken
Journal:  ACS Chem Biol       Date:  2015-10-22       Impact factor: 5.100

3.  Recognition of HIV-inactivating peptide triazoles by the recombinant soluble Env trimer, BG505 SOSIP.664.

Authors:  Kriti Acharya; Adel A Rashad; Francesca Moraca; Per Johan Klasse; John P Moore; Cameron Abrams; Irwin Chaiken
Journal:  Proteins       Date:  2017-03-11

4.  Peptide-Based HIV Entry Inhibitors.

Authors:  Jing Pu; Qian Wang; Shibo Jiang
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  Peptide triazole inactivators of HIV-1: how do they work and what is their potential?

Authors:  Irwin Chaiken; Adel A Rashad
Journal:  Future Med Chem       Date:  2015-11-24       Impact factor: 3.808

6.  Bifunctional Chimera That Coordinately Targets Human Immunodeficiency Virus 1 Envelope gp120 and the Host-Cell CCR5 Coreceptor at the Virus-Cell Interface.

Authors:  Adel A Rashad; Li-Rui Song; Andrew P Holmes; Kriti Acharya; Shiyu Zhang; Zhi-Long Wang; Ebony Gary; Xin Xie; Vanessa Pirrone; Michele A Kutzler; Ya-Qiu Long; Irwin Chaiken
Journal:  J Med Chem       Date:  2018-06-01       Impact factor: 7.446

7.  Macrocyclic Envelope Glycoprotein Antagonists that Irreversibly Inactivate HIV-1 before Host Cell Encounter.

Authors:  Adel A Rashad; Ramalingam Venkat Kalyana Sundaram; Rachna Aneja; Caitlin Duffy; Irwin Chaiken
Journal:  J Med Chem       Date:  2015-09-11       Impact factor: 7.446

Review 8.  Therapeutic potential of HIV-1 entry inhibitor peptidomimetics.

Authors:  Nneka Pu Korie; Kwesi Z Tandoh; Samuel K Kwofie; Osbourne Quaye
Journal:  Exp Biol Med (Maywood)       Date:  2021-02-17

9.  Synthesis and Biological Activities of Ethyl 2-(2-pyridylacetate) Derivatives Containing Thiourea, 1,2,4-triazole, Thiadiazole and Oxadiazole Moieties.

Authors:  Daniel Szulczyk; Piotr Tomaszewski; Michał Jóźwiak; Anna E Kozioł; Tadeusz Lis; David Collu; Filippo Iuliano; Marta Struga
Journal:  Molecules       Date:  2017-03-06       Impact factor: 4.411

10.  Peptide Triazole Thiol Irreversibly Inactivates Metastable HIV-1 Env by Accessing Conformational Triggers Intrinsic to Virus-Cell Entry.

Authors:  Charles Gotuaco Ang; Erik Carter; Ann Haftl; Shiyu Zhang; Adel A Rashad; Michele Kutzler; Cameron F Abrams; Irwin M Chaiken
Journal:  Microorganisms       Date:  2021-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.